Cargando…

Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer

BACKGROUND: Drug and antibody delivery to brain metastases has been highly debated in the literature. The blood-tumor barrier (BTB) is more permeable than the blood-brain barrier (BBB), and has shown to have highly functioning efflux transporters and barrier properties, which limits delivery of targ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terrell-Hall, Tori B., Nounou, Mohamed Ismail, El-Amrawy, Fatema, Griffith, Jessica I.G., Lockman, Paul R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663550/ https://www.ncbi.nlm.nih.gov/pubmed/29137378 http://dx.doi.org/10.18632/oncotarget.19634

Ejemplares similares

Are Currently Available Wearable Devices for Activity Tracking and Heart Rate Monitoring Accurate, Precise, and Medically Beneficial?
por: El-Amrawy, Fatema, et al.
Publicado: (2015)

NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer
por: Adkins, Chris E., et al.
Publicado: (2015)

P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model
por: Adkins, Chris E., et al.
Publicado: (2013)

Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies
por: Nounou, Mohamed I., et al.
Publicado: (2015)

Inhibition of VEGF and Angiopoietin-2 to Reduce Brain Metastases of Breast Cancer Burden
por: Bohn, Kaci A., et al.
Publicado: (2017)

Permeability across a novel microfluidic blood-tumor barrier model
por: Terrell-Hall, Tori B., et al.
Publicado: (2017)

Population-based outcomes after brain radiotherapy in patients with brain metastases from breast cancer in the Pre-Trastuzumab and Trastuzumab eras
por: Karam, Irene, et al.
Publicado: (2013)

Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
por: Kabraji, Sheheryar, et al.
Publicado: (2023)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
por: Rudkouskaya, Alena, et al.
Publicado: (2020)

Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment
por: Baker, Jennifer Hazel Elizabeth, et al.
Publicado: (2018)

Tunicamycin enhances the antitumor activity of trastuzumab on breast cancer in vitro and in vivo
por: Han, Xiqian, et al.
Publicado: (2015)

Predicting perfect drug candidates: Molecular docking 2.0
por: Nounou, Mohamed Ismail
Publicado: (2014)

Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases
por: Page, David B., et al.
Publicado: (2022)

Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases
por: Mills, Matthew N., et al.
Publicado: (2021)

Radiolabeled Trastuzumab Solid Lipid Nanoparticles for Breast Cancer Cell: in Vitro and in Vivo Studies
por: Ozgenc, Emre, et al.
Publicado: (2022)

Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death
por: Le Scodan, Romuald, et al.
Publicado: (2011)

Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab
por: Bergen, Elisabeth Sophie, et al.
Publicado: (2021)

Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
por: Clayton, A J, et al.
Publicado: (2004)

Trastuzumab- and Fab′ fragment-modified curcumin PEG-PLGA nanoparticles: preparation and evaluation in vitro and in vivo
por: Duan, Dongyu, et al.
Publicado: (2018)

Synergistic Effects of Metformin and Trastuzumab on HER2 Positive Gastroesophageal Adenocarcinoma Cells In Vitro and In Vivo
por: Kim, Jin-Soo, et al.
Publicado: (2023)

Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
por: Ferraro, Emanuela, et al.
Publicado: (2022)

Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
por: Bartsch, Rupert, et al.
Publicado: (2022)

Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)
por: Niikura, Naoki, et al.
Publicado: (2023)

HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen
por: Wu, Scott A, et al.
Publicado: (2023)

Enhanced Multiscale Principal Component Analysis for Improved Sensor Fault Detection and Isolation
por: Malluhi, Byanne, et al.
Publicado: (2022)

Preclinical and clinical efficacy of trastuzumab-deruxtecan in breast cancer brain metastases: a new insight on central nervous system activity
por: Batista, Marta Vaz, et al.
Publicado: (2023)

Response of Brain and Meningeal Metastases to Trastuzumab-Deruxtecan in a Patient with HER2-Low Breast Cancer: A Case Report
por: Wolf, Benita, et al.
Publicado: (2023)

Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data
por: Lin, Nancy U., et al.
Publicado: (2023)

Pimenta Oil as a Potential Treatment for Acinetobacter baumannii Wound Infection: In Vitro and In Vivo Bioassays in Relation to Its Chemical Composition
por: Ismail, Maha M., et al.
Publicado: (2020)

Intervention in Biological Phenomena via Feedback Linearization
por: Fnaiech, Mohamed Amine, et al.
Publicado: (2012)

Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo
por: Barok, Mark, et al.
Publicado: (2011)

Electrosteric stealth Rivastigmine loaded liposomes for brain targeting: preparation, characterization, ex vivo, bio-distribution and in vivo pharmacokinetic studies
por: Nageeb El-Helaly, Sara, et al.
Publicado: (2017)

(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
por: Kurihara, Hiroaki, et al.
Publicado: (2015)

Trastuzumab Deruxtecan Improves Progression-Free Survival and Intracranial Response in Patients with HER2-Positive Metastatic Breast Cancer and Brain Metastases
por: Jacobson, Anne
Publicado: (2022)

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
por: Jerusalem, Guy, et al.
Publicado: (2022)

Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study
por: Sanglier, Thibaut, et al.
Publicado: (2023)

Optimal reference sequence selection for genome assembly using minimum description length principle
por: Wajid, Bilal, et al.
Publicado: (2012)

Reverse Engineering Sparse Gene Regulatory Networks Using Cubature Kalman Filter and Compressed Sensing
por: Noor, Amina, et al.
Publicado: (2013)

Prognostic value of right ventricular diastolic dysfunction in patients with inferior ST-elevated myocardial infarction
por: El Amrawy, Ahmed Mahmoud, et al.
Publicado: (2023)

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
por: El-Sahwi, K, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_bqj8o61vh2313c8smfj06bjdoi